Navigation Links
Novartis Drug Diovan Shows Superior Benefits

Results of a Japanese study have given drug giant Novartis AG, more reasons to smile. According to the study published in The Lancet, the company’s blood pressure// drug Diovan was observed to reduce the risks of strokes and cardiovascular events by up to 40 percent.

The study titled the Jikei Heart Study, was based on 3,000 people aged 20 to 79, with high blood pressure, ischemic heart disease or congestive heart failure. The study which was published recently in The Lancet, showed that Diovan produced a 39 percent reduction in cardiovascular events and a 40 percent cut in strokes.

The study compared Diovan when added to a conventional non-angiotensin receptor blocker (ARB) versus the non-ARB therapy alone. Accordingly, the superior benefits reported with Diovan led to an early termination of the study.

In addition to its impact on overall cardiovascular events and stroke, other benefits of Diovan demonstrated were: relative reductions of 65 percent in angina pectoris, 46 percent in heart failure and 81 percent in aortic dissection - separation of the wall layers in the body's main artery – as compared to other treatment groups.

There were few adverse events (2.5 percent overall) with no significant difference in tolerability between the groups. According to investigators, these effects were reported independently of blood pressure reductions.

Says Gordon McInnes, Professor of Medicine at the Western Infirmary in Glasgow, Scotland:"The results of this trial carry an important clinical message for physicians across the globe who are trying to protect patients from debilitating complications such as stroke. "Jikei Heart tells us that adding Diovan to usual treatment regimens can offer substantial long-term protection”, he added.

The Jikei Heart Study is the first controlled trial to assess the cardiovascular benefits of adding the angiotensin receptor blocker, or ARB, Diovan to conventional non-A RB therapy, compared to non-ARB therapy alone- in a large Japanese population. Key events evaluated as part of the primary endpoint included heart attack, stroke and hospitalization for heart failure or angina pectoris.

"Innovative clinical trials have helped Diovan to advance cardiovascular patient care,” Ameet Nathwani, Global Head of Cardiovascular and Metabolic Clinical Research, Development and Medical Affairs, Novartis Pharma AG was quoted. "The results of the independent Jikei Heart Study add to the already large body of evidence demonstrating Diovan's efficacy in lowering blood pressure and preventing cardiovascular events”, he added, welcoming the results.
AN/M
'"/>




Related medicine news :

1. Novartis files application with FDA for Zometa
2. Canine Painkiller unveiled by Novartis
3. Glivec the hot cancer drug from Novartis
4. Zometa [Novartis Drug] For Treatment Of Paget’s Diseas
5. Novartis MS Drug Shows Promising Results
6. Bird-flu Vaccine Adjuvant Contract Goes to Novartis
7. Drop Patent Petition, Activists Ask Novartis
8. E.U. Panel Backs Novartis Mock-up Pandemic Flu Vaccine
9. Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board
10. Novartis Gleevec Found Effective in Treating Gastro-intestinal Tumors
11. Experimental treatment for Ebola Virus Shows promising results in mice
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/15/2017)... ... August 15, 2017 , ... ... at his Inauguration that WesternU will move forward in bold new directions while ... WesternU combined Wilson’s Inauguration ceremony with Convocation, the traditional opening of the academic ...
(Date:8/15/2017)... ... August 15, 2017 , ... Horizon Goodwill is honored to ... are overwhelmed with gratitude for the very generous donation from BB&T. Our mission ... both get a job and keep it. This donation will go a long ...
(Date:8/15/2017)... ... August 15, 2017 , ... IsoComforter, Inc., one of the ... innovative new 10x10 bladder pad ( isocomforter.com/product/10x10-sterile-pad/ ). The newly designed bladder pad ... enables the patient to enjoy the benefits of cold therapy while resting, sitting, ...
(Date:8/15/2017)... ... August 15, 2017 , ... Harris Communications, Inc. is bringing its ... Twin Cities Living Well with Hearing Loss Conference, 9:30-2 p.m. Saturday, Nov. 18 at ... for Harris Communications at tables 8 and 9. , During the conference, attendees can ...
(Date:8/15/2017)... Glan Allen,VA (PRWEB) , ... August 15, 2017 ... ... of CoolSculpting to their leading selection of services. FDA-cleared CoolSculpting is the world’s ... and counting. Without surgery or downtime, CoolSculpting can reduce fat cells in almost ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... Services, Inc. (NYSE: WST ) today announced ... financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record high, ... constant currency (organic) grew by 3.9%. ... in the prior-year quarter. Second-quarter 2017 adjusted diluted EPS ...
(Date:7/26/2017)... July 26, 2017 Sancilio Pharmaceuticals Company, Inc. ... clinical trial evaluating Altemia TM , an oral therapy ... Sickle Cell Disease (SCD). The SCOT Trial, is a ... and safety of Altemia TM in pediatric patients ... US IND 125274. ...
(Date:7/25/2017)... -- Debbie,s Dream Foundation: Curing Stomach Cancer (DDF) is excited to host its 3 ... Bonaventure Resort & Spa in Weston, Florida beginning at ... Luncheon Committee Co-chair ... Luncheon Committee Co-chair Sabrina Kurzman. ... Aura Morales-Guzman, Angela Perez, DDF Board Member John ...
Breaking Medicine Technology: